SupplemeNt to FREE 2.75 CME CREDITS This supplement was edited and peer-reviewed by The Journal of Family Practice. Available at jfponline.com Vol 59, No 4 / APRIl 2010 The dawn of a new era: Transforming our domestic response to hepatitis B & C } Anna S. F. Lok, MD, FRCP, Coeditor } Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, Coeditor heaA CONTINUINGlthma MEDICAL tEDUCAterTIONscm COMPANYe This activity is supported by independent educational grants Jointly sponsored by Postgraduate provided by Bristol-Myers Squibb, Gilead Sciences Inc., and Institute for Medicine and Vertex Pharmaceuticals. HealthmattersCME. S2 April 2010 | Vol 59, No 4 | Supplement to The Journal of Family Practice The dawn of a new era: Transforming our domestic response to hepatitis B & C Release Date: April 1, 2010 • Outline the most recent recommendations from the Cen- Expiration Date: April 1, 2011 ters for Disease Control and Prevention on screening and Estimated time to complete activity: 2.75 hours managing HBV and HCV infections in clinical practice • Differentiate among available therapeutic agents for HBV healthmatterscme A CONTINUING MEDICAL EDUCATION COMPANY and HCV to optimize treatment • Identify factors that might affect the response to treat- This activity is jointly sponsored by Postgraduate Institute for ment of infected individuals Medicine and HealthmattersCME. • Describe specific treatment and management strategies in order to delay the onset of liver disease • Identify the ethnic, racial, and socioeconomic disparities This activity is supported by independent educational grants in chronic liver disease, including hepatocellular carcino- provided by Bristol-Myers Squibb, Gilead Sciences Inc., and ma, and screening Vertex Pharmaceuticals. • Specify strategies to overcome ethnic, racial, and socio- economic disparities in the screening and diagnosis of CME INFORMATION patients with chronic liver disease How to obtain CME credit Please go online to http://www.cmeuniversity.com and enter PHYSICIAN CONTINUING MEDICAL EDUCATION Course ID 7130 and complete the posttest, evaluation, and Accreditation Statement credit request in order to receive CME credit for “The dawn of This activity has been planned and implemented in accor- a new era: Transforming our domestic response to hepatitis dance with the Essential Areas and Policies of the Accredi- B & C.” tation Council for Continuing Medical Education (ACCME) You will be able to print out your certificate upon notifica- through the joint sponsorship of Postgraduate Institute for tion that you have passed the posttest with a score of 70% Medicine (PIM) and HealthmattersCME. PIM is accredited or better. by the ACCME to provide continuing medical education PROGRAM OVERVIEW for physicians. Diseases associated with hepatitis B virus (HBV) and hepati- Credit Designation tis C virus (HCV) create a considerable burden on the nation’s PIM designates this educational activity for a maximum of health care system and pose many challenges in terms of ef- 2.75 AMA PRA Category 1 Credits™. Physicians should only fective identification, treatment, and patient management. claim credit commensurate with the extent of their participa- Both chronic HBV and HCV infections are often asymptomatic, tion in the activity. earning them reputations as silent killers. Many individuals are unaware that they are infected until they develop signs DISCLOSURE OF CONFLICTS OF INTEREST or symptoms of cirrhosis or liver cancer. As many as 2 million Americans are infected with HBV and 5 million are infected PIM assesses conflict of interest with its instructors, planners, with HCV. Despite this large patient population, standards for managers, and other individuals who are in a position to con- virus prevention, screening, and clinical care are currently in- trol the content of CME activities. All relevant conflicts of in- adequate, resulting in a major unmet medical need. terest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, TARGET AUDIENCE and patient care recommendations. PIM is committed to pro- viding its learners with high-quality CME activities and related This activity has been designed to meet the educational needs materials that promote improvements or quality in health of physicians and physician assistants involved in the care of care and not a specific proprietary business interest of a com- patients with chronic HBV and HCV. mercial interest. The planners and managers reported the following finan- EDUCATIONAL OBJECTIVES cial relationships or relationships to products or devices they After completing this activity, the participant should be better or their spouse/life partner have with commercial interests re- able to: lated to the content of this CME activity: • Describe the need for a coordinated national response to PIM planners and managers—Jan Hixon, RN, BSN, MA; Trace chronic HBV and HCV Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiuc- • Identify improved strategies for the screening, diagnosis, ci, PharmD; and Jan Schultz, RN, MSN, CCMEP—hereby state treatment, and care of people with HBV or HCV that they or their spouse/life partner do not have any financial Supplement to The Journal of Family Practice | Vol 59, No 4 | April 2010 S3 The dawn of a new era: Transforming our domestic response to hepatitis B & C relationships or relationships to products or devices with any Method of Participation commercial interest related to the content of this activity of any There are no fees for participating and receiving CME credit for amount during the past 12 months. this activity. During the period April 1, 2010, through April 1, HealthmattersCME planners and manager—James Murphy 2011, participants must (1) read the learning objectives and fac- and Yelena Lyustikman—hereby state that they or their spouse/ ulty disclosures; (2) study the educational activity; (3) complete life partner do not have any financial relationships or relation- the posttest by going to http://www.cmeuniversity.com, enter- ships to products or devices with any commercial interest relat- ing Course ID 7130, and recording the best answer to each ques- ed to the content of this activity of any amount during the past tion; and (4) complete the evaluation form and credit request. 12 months. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest DISCLOSURE OF UNLABELED USE with a score of 70% or better. This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by DISCLAIMER the FDA. PIM, HealthmattersCME, Bristol-Myers Squibb, Gilead Participants have an implied responsibility to use the newly ac- Sciences Inc., and Vertex Pharmaceuticals do not recommend quired information to enhance patient outcomes and their own the use of any agent outside of the labeled indications. professional development. The information presented in this The opinions expressed in the educational activity are those activity is not meant to serve as a guideline for patient manage- of the faculty and do not necessarily represent the views of PIM, ment. Any procedures, medications, or other courses of diagno- HealthmattersCME, Bristol-Myers Squibb, Gilead Sciences Inc., sis or treatment discussed or suggested in this activity should and Vertex Pharmaceuticals. Please refer to the official prescrib- not be used by clinicians without evaluation of their patient’s ing information for each product for discussion of approved in- conditions and possible contraindications on dangers in use, re- dications, contraindications, and warnings. view of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. S4 April 2010 | Vol 59, No 4 | Supplement to The Journal of Family Practice Disclosure Information Harvey J. Alter, MD, MACP Speakers Bureau: Abbott, Centocor Dr Alter has no real or apparent conflicts of interest to report. Edward C. Doo, MD Miriam J. Alter, PhD Dr Doo has no real or apparent conflicts of interest to report. Dr Alter has no real or apparent conflicts of interest to report. Brian R. Edlin, MD Janelle Tangonan Anderson, MA Dr Edlin has no real or apparent conflicts of interest to report. Ms Anderson has no real or apparent conflicts of interest to report. Hashem B. El-Serag, MD, MPH Dr El-Serag has no real or apparent conflicts of interest William B. Baine, MD to report. Dr Baine has no real or apparent conflicts of interest to report. Ted Fang Joan M. Block, RN, BSN Mr Fang has no real or apparent conflicts of interest to report. Ms Block has no real or apparent conflicts of interest to report. Garth N. Graham, MD, MPH Jeffrey B. Caballero, MPH Dr Graham has no real or apparent conflicts of interest Mr Caballero has no real or apparent conflicts of interest to report. to report. Charles D. Howell, MD Denton Chase Consultant: Abbott, Roche Pharmaceuticals, Vertex Mr Chase has no real or apparent conflicts of interest to report. Pharmaceuticals Speakers Bureau: Vertex Pharmaceuticals Laura W. Cheever, MD, ScM Dr Cheever has no real or apparent conflicts of interest Dale J. Hu, MD, MPH to report. Dr Hu has no real or apparent conflicts of interest to report. Edward A. Chow, MD Ira M. Jacobson, MD Dr Chow has no real or apparent conflicts of interest to report. Consultant: Abbott, Anadys, Boehringer Ingelheim, Bristol- Myers Squibb, Gilead Sciences Inc., GlobeImmune, Inc, Human Corinna Dan, RN, MPH